Allarity receives FDA Fast Track for stenoparib in advanced ovarian cancer

Allarity Therapeutics, Inc.

FDA granted Fast Track designation to stenoparib for advanced ovarian cancer on August 26, 2025.
Fast Track enables expedited development, potential accelerated/priority review and rolling review.
Company began Phase 2 enrollment in June 2025; several patients already dosed.
Prior Phase 2 data showed durable clinical benefit including patients on treatment >22 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.